IGM Biosciences Inc Stock News

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of IGM Biosciences, Inc. (NASDAQ: IGMS) to Concentra Biosciences, LLC is fair to IGM shareholders. Under the terms of the proposed transaction, IGM shareholders would receive $1.247 in cash per share, plus one non-tradeable contingent value right, representing the right to receive additio...

MOUNTAIN VIEW, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a biotechnology company that has focused on developing engineered IgM-based therapeutic antibodies, today announced that it has entered into a definitive merger agreement (the “Merger Agreement”) with Concentra Biosciences, LLC (“Concentra”), whereby Concentra will acquire IGM Biosciences for $1.247 i...